Sugi Predict

Sugi Predict / Compounds / SCHEMBL3021150

SCHEMBL3021150

SCHEMBL3021150

Cc1cc(Nc2c3nccn3nc(N)c2[C@H]2CC[C@H](N)CC2)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.37
▸ TDO2 P48775 2/20 0.37
▸ CDK2 P24941 5/20 0.35
▸ FLT3 P36888 2/20 0.35
▸ CCNE1 P24864 1/20 0.35
▸ KCNQ3 O43525 2/20 0.34
▸ KCNQ2 O43526 2/20 0.34
▸ MAPKAPK2 P49137 4/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CSNK1D P48730 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ MAPKAPK3 Q16644 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ RAPGEF4 Q8WZA2 2/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ MAPK9 P45984 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ MAP2K1 Q02750 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020715 0.92 CDK2 (0.35) CDK2FLT3CCNE1MAPKAPK2CHEK2
SCHEMBL3021744 0.91 CDK2 (0.36) TDO2CDK2FLT3CCNE1MAPKAPK2
SCHEMBL3017867 0.91 FLT3 (0.36) LMNATDO2CDK2FLT3CCNE1
SCHEMBL3027054 0.91 FLT3 (0.36) LMNATDO2CDK2FLT3CCNE1
SCHEMBL3023223 0.89 IDO1 (0.37) TDO2CDK2FLT3CCNE1MAPKAPK2
SCHEMBL3533300 0.87 FLT3 (0.35) TDO2CDK2FLT3CCNE1CDK1
SCHEMBL3021677 0.86 CCNE1 (0.38) TDO2CDK2FLT3CCNE1MAPKAPK2
SCHEMBL3012714 0.86 CCNE1 (0.38) TDO2CDK2FLT3CCNE1MAPKAPK2
SCHEMBL3018529 0.86 FLT3 (0.38) TDO2CDK2FLT3CCNE1KCNQ3
SCHEMBL3024787 0.85 PAK4 (0.35) CDK2FLT3CCNE1KCNH2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928879-B1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-02-13 — — EP claimed
US-7723336-B2 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-25 — — US claimed
EP-1928879-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS Brystol-Myers Squibb Company (US) 2008-06-11 — — EP claimed
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US claimed
WO-2007038314-A2 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-05 — — WO claimed
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 — — US claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 — — US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 — — US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 — — US disclosed
EP-1928879-B1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-02-13 — — EP disclosed
US-20100204212-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 — — US disclosed
US-7723336-B2 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-25 — — US disclosed
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-02-21 — — US disclosed
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators MAP3K2, MAP3K3, MAP4K2 LMNA 4763/4885TDO2 3618/4885CDK2 50/4885
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 LMNA 1390/4885TDO2 326/4885CDK2 665/4885
US-20100204212-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS MAP2K2, MAP3K2, MAP4K2 LMNA 4313/4885TDO2 3885/4885CDK2 40/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 LMNA 1390/4885TDO2 326/4885CDK2 665/4885
US-20080045536-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS MAP3K3, MAP3K2, MAP4K3 LMNA 4523/4885TDO2 3750/4885CDK2 67/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 LMNA 1390/4885TDO2 326/4885CDK2 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.